In obstructive sleep apnea syndrome (OSA) the periodic reduction or cessation of breathing due to narrowing or occlusion of the upper airway during sleep leads to an impaired cerebral vascular autoregulation that is associated with an increased cardiovascular risk, including stroke. Continuous positive airways pressure (CPAP) therapy at night is the most effective treatment for OSA and has been shown to reduce the cardiovascular risk in OSA patients. However, there is no suitable bedside monitor
